

Jonathan D. Marmur, MD, FACC, FRCP
Director of Cardiac Catheterization and Interventional Cardiology
SUNY Health Science Center at Brooklyn
450 Clarkson Avenue, Box 1257
Brooklyn, NY 11203-2098

jonathan@marmur.com

Direct Office Line (no voice mail)	718-270-7383
Office Fax	917-595-5318
Cellular Phone	917-885-8854

CERTIFICATION

American Board Certification in Interventional Cardiology, Nov 2010

Certification Board of Cardiovascular Computed Tomography, Dec 2008

American Board Certification in Interventional Cardiology, Nov 2000

FACC- Fellow of the American College of Cardiology, Feb 1995

American Board Certification in Cardiology, March 1990

Certificate of Competence in Cardiology, Royal College of Physicians of Canada, Nov 1988

FRCP- Fellow of the Royal College of Physicians and Surgeons of Canada, Specialist in Internal Medicine, June 1987

Diplomat of the American Board of Internal Medicine, Jan 1987

Diplomat of the National Board of Medical Examiners (USA), July 1983

Licentiate of the Medical Council of Canada, June 1982

MD: Laval University (Quebec City, Canada), May 1982

APPOINTMENTS

April 2007-present: Editorial Board of the Journal of Cardiovascular Revascularization Medicine

March 2007- present: Editorial Board of the Journal of Invasive Cardiology

September 2005-present: Professor of Medicine, State University of New York Health Science Center at Brooklyn, NY

June 2005-present: Research Core Director for NIH-sponsored Brooklyn Center for Health Disparities

April 2004-present: Director of Clinical Research, Center for Cardiovascular and Muscle Research (CCMR), State University of New York at Brooklyn, NY

January 2003-present: Director of Interventional Cardiology Fellowship Program, State University of New York Health Science Center at Brooklyn, NY

January 2003- 2005: Editorial Board of the Journal of Cardiovascular Revascularization Medicine

January 2003-Sept 2005: Associate Professor of Medicine, State University of New York Health Science Center at Brooklyn, NY

July 2001-2005: Editorial Board of the Journal of the American College of Cardiology

January 1994-Dec 2002: Assistant Professor of Medicine, Attending Interventional Cardiologist, Mt. Sinai School of Medicine, NY

July 1992-Dec 1993: Instructor in Medicine, Mt. Sinai School of Medicine, NY

July 1988-June 1992: Cardiology Research Fellow and Coronary Angioplasty Fellow, Mount Sinai Medical Center, NY

July 1986-June 1988: Clinical Cardiology Fellow: St. Michael's Hospital and Mount Sinai Hospital, University of Toronto, Canada

July 1983-June 1986: Internal Medicine Resident: Montreal General Hospital, McGill University, Canada

July 1982-June 1983: Intern: Queen Elizabeth Hospital, McGill University, Canada

AWARDS

July 1997: Preceptor to recipient of the American College of Cardiology/Merck Adult Cardiology Research Fellowship Award for 1997-98

June 1995: NIH General Clinical Research Center Award (Principal Investigator for Cardiovascular Project)

June 1994: NIH Clinical Investigator Development Award (KO8 HL03210-01)

June 1992: Denber Research Award for Excellence in Cardiovascular Research

March 1992: American College of Cardiology, New York State Chapter Young Investigators Honorable Mention Award

Oct. 1990: Mt. Sinai Hosp., NY, Annual Research Day Award

June 1990: Medical Research Council of Canada Fellowship Award

July 1988: Canadian Heart and Stroke Foundation Research Fellowship Award

May 1987: Ursula Bangs Research Competition Award, University of Toronto

PUBLICATIONS

ORIGINAL ARTICLES

Azari BM, Marmur JD, Salifu MO, Ehrlich YH, Kornecki E, Babinska A. Transcription and translation of human F11R gene are required for an initial step of atherogenesis induced by inflammatory cytokines. *J Transl Med.* 2011;9:98 [Epub ahead of print]

Azari BM, Marmur JD, Salifu MO, Cavusoglu E, Ehrlich YH, Kornecki E, Babinska A. Silencing of the F11R gene reveals a role for F11R/JAM-A in the migration of inflamed vascular smooth muscle cells and in atherosclerosis. *Atherosclerosis.* 2010;212:197-205.

Cavusoglu E, Ruwende C, Chopra V, Poludasu S, Yanamadala S, Frishman WH, Eng C, Pinsky DJ, Marmur JD. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. *Atherosclerosis.* 2010;210:226-31.

Poludasu S, Cavusoglu E, Khan W, Marmur JD. Neutrophil to lymphocyte ratio as a predictor of long-term mortality in African Americans undergoing percutaneous coronary intervention. *Clin Cardiol.* 2009;32:E6-E10.

Marmur JD, Bullock-Palmer RP, Poludasu S, Cavusoglu E. Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention. *J Invasive Cardiol.* 2009;21:653-64.

Poludasu S, Marmur JD, Weedon J, Khan W, Cavusoglu E. Red cell distribution width (RDW) as a predictor of long-term mortality in patients undergoing percutaneous coronary intervention. *Thromb Haemost.* 2009;102:581-7.

Cavusoglu E, Marmur JD, Chhabra S, Chopra V, Eng C, Jiang XC. Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography. *Atherosclerosis.* 2009;207:261-5.

Cavusoglu E, Chopra V, Gupta A, Choksi PU, Ruwende C, Yanamadala S, Frishman WH, Pinsky DJ, Marmur JD. Relation of baseline serum potassium levels to

angiographic findings in patients with known or suspected coronary artery disease. *Am J Hypertens.* 2009;22:754-62.

Poludasu S, Marmur JD, Weedon J, Khan W, Cavusoglu E. Effect of hemoglobin level on long-term all-cause mortality after percutaneous coronary intervention in African-Americans. *Am J Cardiol.* 2009;103:1078-82.

Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Pinsky DJ, Marmur JD. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography. *Coron Artery Dis.* 2009;20:112-117.

Marmur JD, Poludasu S, Lazar J, Cavusoglu E. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention. *Catheter Cardiovasc Interv.* 2009;73:214-221.

Cavusoglu E, Chopra V, Gupta A, Battala VR, Poludasu S, Eng C, Marmur JD. Relation between red blood cell distribution width (RDW) and all-cause mortality at two years in an unselected population referred for coronary angiography. *Int J Cardiol.* 2009 Jan 12.

Poludasu S, Cavusoglu E, Khan W, Marmur JD. Impact of body mass index on long-term all-cause mortality after percutaneous coronary intervention in African-Americans. *J Invasive Cardiol.* 2009;21:20-25.

Poludasu S, Cavusoglu E, Khan W, Marmur JD. All-cause mortality after drug-eluting stent implantation in African-Americans. *Coron Artery Dis.* 2008;19:551-557.

Marmur JD, Lakhani M, El Rouby S, Cavusoglu E. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory. *J Invasive Cardiol.* 2008;20:449-454.

Marmur JD, Poludasu S, Feit A, Battala VR, Cavusoglu E. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention. *J Invasive Cardiol.* 2008;20:323-327.

Cavusoglu E, Chopra V, Battala V, Ruwende C, Yanamadala S, Eng C, Pinsky DJ, Marmur JD. Baseline plasma adiponectin levels as a predictor of left ventricular systolic dysfunction in patients referred for coronary angiography. *Am J Cardiol.* 2008;101:1073-1078.

Marmur JD, Poludasu S, Agarwal A, Manjappa N, Cavusoglu E. High-dose tirofiban administered as bolus-only during percutaneous coronary intervention. *J Invasive Cardiol.* 2008;20:53-58.

Cavusoglu E, Chhabra S, Jiang XC, Hojjati MR, Chopra V, Eng C, Gupta A, Yanamadala S, Pinsky DJ, Marmur JD. Relation of baseline plasma phospholipid levels to cardiovascular outcomes at two years in men with acute coronary syndrome referred for coronary angiography. *Am J Cardiol.* 2007;100:1739-1743.

Cavusoglu E, Kornecki E, Sobocka MB, Babinska A, Ehrlich YH, Chopra V, Yanamadala S, Ruwende C, Salifu MO, Clark LT, Eng C, Pinsky DJ, Marmur JD.

Association of plasma levels of F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) with human atherosclerosis. *J Am Coll Cardiol.* 2007;50:1768-1776.

Anand SX, Kim MC, Kamran M, Sharma SK, Kini AS, Fareed J, Hoppensteadt DA, Carbon F, Cavusoglu E, Varon D, Viles-Gonzalez JF, Badimon JJ, Marmur JD. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. *Am J Cardiol.* 2007;100:417-424.

Cavusoglu E, Eng C, Chopra V, Ruwende C, Yanamadala S, Clark LT, Pinsky DJ, Marmur JD. Usefulness of the serum complement component C4 as a predictor of stroke in patients with known or suspected coronary artery disease referred for coronary angiography. *Am J Cardiol.* 2007;100:164-168.

Cavusoglu E, Ruwende C, Eng C, Chopra V, Yanamadala S, Clark LT, Pinsky DJ, Marmur JD. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. *Am J Cardiol.* 2007;99:1364-1368.

Poludasu S, Cavusoglu E, Clark LT, Marmur JD. Impact of gender on in-hospital percutaneous coronary interventional outcomes in African-Americans. *J Invasive Cardiol.* 2007;19:123-128.

Babinska A, Azari BM, Salifu MO, Liu R, Jiang XC, Sobocka MB, Boo D, Al Khoury G, Deitch JS, Marmur JD, Ehrlich YH, Kornecki E. The F11 receptor (F11R/JAM-A) in atherothrombosis: Overexpression of F11R in atherosclerotic plaques. *Thromb Haemost* 2007;97:272–281.

Cavusoglu E, Eng C, Chopra V, Clark LT, Pinsky DJ, Marmur JD. Low Plasma RANTES Levels Are an Independent Predictor of Cardiac Mortality in Patients Referred for Coronary Angiography. *Arterioscler Thromb Vasc Biol.* 2007;27:929-935.

Sobocki T, Jayman F, Sobocka MB, Marmur JD, Banerjee P. Isolation, sequencing, and functional analysis of the TATA-less murine ATPase II promoter and structural analysis of the ATPase II gene. *Biochimica et Biophysica Acta* 2007;1769:61–75.

Marmur JD, Poludasu S, Agarwal A, Vladutiu P, Feit A, Lapin R, Cavusoglu E. Bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention. *J Invasive Cardiol.* 2006;18:521-526.

Marmur JD, Mitre CA, Barnathan E, Cavusoglu E. Benefit of Bolus-Only Platelet Glycoprotein IIb/IIIa Inhibition During Percutaneous Coronary Intervention: Insights From the Very Early Outcomes in the EPIC Trial. *Am Heart J.* 2006; 2006;152:876-881.

Cavusoglu E, Chopra V, Gupta A, Ruwende C, Yanamadala S, Eng C, Clark LT, Pinsky DJ, Marmur JD. Usefulness of the white blood cell count as a predictor of angiographic findings in an unselected population referred for coronary angiography. *Am J Cardiol* 2006;98:1189 –1193.

Cavusoglu E, Chopra V, Gupta A, Clark LT, Eng C, Marmur JD. Usefulness of anemia in men as an independent predictor of two-year cardiovascular outcome in patients presenting with acute coronary syndrome. *Am J Cardiol* 2006;98:580-584.

Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, Pinsky DJ, Marmur JD. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. *Eur Heart J*. 2006;27:2300-2309.

Akerman MJ, Yaegashi M, Khiangte Z, Murugan AT, Abe O, Marmur JD. Bronchodilator effect of infused B-type natriuretic peptide in asthma. *Chest* 2006;130:66-72

Kokolis S, Marmur JD, Clark LT, Kassotis J, Kokolis R, Cavusoglu E, Lapin R, Breitbart S, Lazar JM. Effects of alcoholism on coronary artery disease and left ventricular dysfunction in male veterans. *J Invasive Cardiol*. 2006;18:304-307.

Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, Pinsky DJ, Marmur JD. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. *Am Heart J*. 2006 May;151(5):1108.e1-8.

Cavusoglu E, Lakhani M, Marmur JD. The Activated Clotting Time (ACT) Can Be Used to Monitor Enoxaparin and Dalteparin after Intravenous Administration. *J Invasive Cardiol* 2005;17:416-421.

Richardson MW, Hostalek L, Michellebson M, Hu J, Shippy R, Siwkowski A, Marmur JD, Khalili K, Klotman PE, Hampel A, Rappaport J. Design, Targeting, and Initial Screening of sTRSV- Derived Hairpin Ribozymes for Optimum Helix 1 Length and Catalytic Efficiency In Vitro. *Methods Mol Biol* 2004;252:339-358.

Kini AS, Lee P, Marmur JD, Agarwal A, Duffy ME, Kim MC, Sharma SK. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. *Am J Cardiol* 2004;93:18-23.

Sharma SK, Kini A, Mehran R, Lansky A, Kobayashi Y, Marmur JD. Randomized trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-stent Restenosis (ROSTER). *Am Heart J* 2004;147:16-22.

Kini AS, Lee PC, Mitre CA, Kim MC, Kamran M, Duffy ME, Marmur JD, Sharma SK. Prediction of outcome after percutaneous coronary intervention for the acute coronary syndrome. *Am J Med* 2003;115:708-714.

Doshi SN, Kini A, Kim MC, Payne N, Kamran M, Sherman W, Marmur JD, Sharma SK. A comparative study of rotational atherectomy in acute and stable coronary syndromes in the modern era. *Am J Cardiol* 2003;92:1404-1408.

Marmur JD, Anand SX, Bagga RS, Fareed J, Pan C-M, Sharma SK, Richard MF. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. *J Am Coll Cardiol* 2003;41:394-402.

Kini AS, Richard M, Suleman J, Perez N, Lee P, Fisher EA, Kamran M, Marmur JD, Sharma SK. Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). *Am J Cardiol* 2002;90:526-529.

Lev EI, Marmur JD, Zdravkovic M, Osende JI, Robbins J, Delfin JA, Richard M, Erhardtson E, Thomsen MS, Lincoff AM, Badimon JJ. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa; an ex-vivo human study. *Arterioscler Thromb Vasc Biol* 2002;22: 1036-1041.

Cavusoglu E, Chen I, Rappaport J, Marmur JD. Inhibition of tissue factor gene induction and activity using a hairpin ribozyme. *Circulation* 2002;105:2282-2287.

Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. *Circulation* 2002;105: 1291-1297.

Kini AS, Mitre CA, Kamran M, Suleman J, Kim M, Duffy ME, Marmur JD, Sharma SK. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. *Am J Cardiol* 2002;89: 999-1002.

Osende JI, Fuster V, Lev EI, Shimbo D, Rauch U, Marmur JD, Richard M, Varon D, Badimon JJ. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests. Relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. *Circulation* 2001;103: 1488-1491.

Lev EI, Osende JI, Richard MF, Robbins JA, Delfin JA, Rodriguez O, Sharma SK, Jayasundera T, Badimon JJ, Marmur JD. Administration of abciximab to patients receiving tirofiban or eptifibatide – effect on platelet function. *J Am Coll Cardiol* 2001;37: 847-855.

Kini A, Reich D, Marmur JD, Mitre CA, Sharma SK. Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions: Results of the Rota ReoPro randomized trial. *Am Heart J* 2001;142: 965-969.

Tan RP, Kini A, Shalouh E, Marmur JD, Sharma SK. Optimal treatment of nonaorto ostial coronary lesions in large vessels: acute and long-term results. *Cathet Cardiovasc Intervent* 2001;54: 283-288.

Sharma SK, Kini A, Marmur JD, Fuster V. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival. *Circulation* 2000;102: 166-172.

Hayes R, Chesebro JH, Fuster V, Dangas G, Fallon JT, Sharma SK, Coller BS, Badimon L, Marmur JD, Badimon JJ. Antithrombotic effects of abciximab. *Am J Cardiol* 2000;85: 1167-1172.

Dangas G, Ambrose JA, Rehmann D, Marmur JD, Sharma SK, Hemdal-Monsen C, Sanborn TA, Fischman DL. Balloon optimization versus stent study (BOSS): provisional stenting and early recoil after balloon angioplasty. *Am J Cardiol* 2000;85: 957-961.

Kini A, Marmur JD, Dangas G, Choudhary S, Sharma SK. Angiographic patterns of in-stent restenosis and implications on subsequent revascularization. *Catheter Cardiovasc Interv*. 2000;49:23-29.

Kini A, Kini S, Marmur JD, Bertea T, Dangas G, Cocke TP, Sharma SK. Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. *Catheter Cardiovasc Interv* 1999;48:123-129.

Kini A, Marmur JD, Kini S, Dangas G, Cocke TP, Wallenstein S, Brown E, Ambrose JA, Sharma SK. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course: implications for early discharge after coronary intervention. *J Am Coll Cardiol* 1999;34:663-671.

Dangas G, Ambrose JA, Sharma SK, Shao JH, Feldman D, Cohen AM, Marmur JD, Cocke TP, Duvvuri S, Goldman ME. The effect of early postinfarction revascularization of asymptomatic patients on left ventricular remodeling. *Coron Artery Dis* 1999;10:203-210.

Dangas G, Marmur JD, King TE, De Leon J, Sharma SK, Vidhun R, Feldman D, Stoyinov MY, Badimon JJ, Ambrose JA. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention. *Am Heart J* 1999;138:49-54.

Kini A, Marmur JD, Duvvuri S, Dangas G, Choudhary S, Sharma SK. Rotational atherectomy: improved procedural outcome with evolution of technique and equipment. Single-center results of first 1,000 patients. *Catheter Cardiovasc Interv* 1999;46:305-311.

Williams MS, Collier BS, Vaananen HJ, Scudder LE, Sharma SK, Marmur JD. Activation of platelets in platelet-rich plasma by rotablation is speed dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro). *Circulation* 1998;98:742-748.

Dangas G, Badimon JJ, Collier BS, Fallon JT, Sharma SK, Hayes RM, Meraj P, Ambrose JA, Marmur JD. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition. Implications for a potential anticoagulant effect of abciximab. *Arterioscler Thromb Vasc Biol* 1998;18:1342-1349.

Dangas G, Peters-Veluthamaningal C, Cocke TP, Vidhun R, Duvvuri S, Marmur JD, Sharma SK. Histopathological correlates of early arterial recoil following directional coronary atherectomy. *Cardiology* 1998;90:32-36

Sharma SK, Duvvuri S, Dangas G, Kini A, Vidhun R, Venu K, Ambrose JA, Marmur JD. Rotational atherectomy for in-stent restenosis: acute and long-term results of the first 100 cases. *J Am Coll Cardiol* 1998;32:1358-65.

Taub PJ, Marmur JD, Zhang WX, Senderoff D, Nhat PD, Phelps R, Urken ML, Silver L, Weinberg H. Locally administered vascular endothelial growth factor cDNA increases survival of ischemic experimental skin flaps. *Plast Reconstr Surg* 1998;102:2033-2039.

Taub PJ, Marmur JD, Zhang WX, Senderoff D, Urken ML, Silver L, Weinberg H. Effect of time on the viability of ischemic skin flaps treated with vascular endothelial growth factor (VEGF) cDNA. *J Reconstr Microsurg* 1998; 14: 387-390.

Dangas G, Cocke TP, Sharma SK, Vidhun RR, Kakarala V, Marmur JD, Ambrose JA. Early Changes in Minimal Luminal Diameter After Balloon Angioplasty and Directional Coronary Atherectomy. *J Invasive Cardiol*. 1998; 7: 372-375.

Sharma SK, Dangas G, Mehran R, Duvvuri S, Kini A, Cocke TP, Kakarala V, Cohen AM, Marmur JD, Ambrose JA. Risk factors for the development of slow flow during rotational coronary atherectomy. *Am J Cardiol* 1997; 80: 219-222.

Marmur JD, Sharma SK, Weinrauch M, Kantrowitz N, Dangas G, Kokinakkis S, Ambrose JA. Thrombin generation and activity during coronary angioplasty: influence of angiographic lesion morphology. *J Inv Cardiol* 1997; 9: 410-416.

Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubman MB. The identification of active tissue factor in human coronary atheroma. *Circulation* 1996; 94: 1226-1238.

Marmur JD, Merlini PA, Sharma SK, Khaghan N, Israel DH, Torre SR, Ardissino D, Ambrose JA. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. *J Am Coll Cardiol* 1994; 24: 1484-1491.

Ambrose JA, Almeida OD, Sharma SK, Torre SR, Marmur JD, Israel DH, Ratner DE, Weiss MB, Monsen CE, Myler RK, Moses J, Unterecker WJ, Grunwald AM, Garrett JS, Cowley MJ, Anwar A, Sobolski J. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA trial. *Circulation* 1994; 90: 69-77.

Alexopoulos D, Sanborn TA, Marmur JD, Badimon JJ, Badimon L, Dische R, Fuster V. Acute biological response to laser balloon angioplasty in the atherosclerotic rabbit. *Lasers Surg Med* 1994; 14: 7-12.

Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. *J Clin Invest* 1993; 91: 2253-9.

Taubman MB, Marmur JD, Rosenfield CL, Guha A, Nichtberger S, Nemerson Y. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells: Role of Ca²⁺ mobilization and protein kinase C activation. *J Clin Invest* 1993; 91: 547-552.

Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS, Berk BC, Nadal-Ginard B. JE mRNA accumulates rapidly in aortic injury and in PDGF-stimulated vascular smooth muscle cells. *Circ Res* 1992; 70: 314-325.

Marmur JD, Sanborn T, Kahn H, Badimon L, Fuster V. The acute biological response to excimer versus thermal laser angioplasty in experimental atherosclerosis. *J Am Coll Card* 1991; 17: 978-84.

Marmur JD, Freeman MR, Langer A, Armstrong PW. Prognosis in medically stabilized unstable angina: early Holter ST segment monitoring vs predischARGE exercise tomography. *Annals of Internal Medicine* 1990; 113:575-579.

Sanborn TA, Alexopoulos DA, Marmur JD, Kahn H, Badimon JJ, Badimon L, Fuster V. Coronary excimer laser angioplasty: reduced complications and Indium-111 platelet accumulation compared to laser thermal angioplasty. *J Am Coll Card* 1990; 16:502-506.

CASE REPORTS

M Kokolis S, Feit A, Marmur JD. Coronary air embolization in the left coronary artery. *J Invasive Cardiol*. 2007;19:47-48.

Mungee S, Lapin R, Cavusoglu E, Clark LT, Marmur JD. Percutaneous coronary intervention in a patient with congenital Factor XI deficiency and acquired inhibitor. *Cardiology* 2006; 107:69–72.

Catheter-induced spasm of the left main coronary artery due to anatomic "kinking" in its course. Lingegowda US, Marmur JD, Cavusoglu E. *J Invasive Cardiol*. 2005; 17:192-194

Doshi SN, Marmur JD. Resolution of intracoronary thrombus with direct thrombin inhibition in a cocaine abuser. *Heart*. 2004; 90:501.

Doshi SN, Marmur JD, Kamran M. Successful use of the Guardwire Plus distal embolisation protection device in a native left anterior descending coronary artery. *Heart*. 2002; 88:648.

Jayasundera TG, Feldman DN, Marmur JD. Tirofiban-induced coronary thrombolysis. *J Invasive Cardiol* 1999; 3:138-140.

REVIEW ARTICLES

Hilleman DE, Tsikouris JP, Seals AA, Marmur JD. Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. *Pharmacotherapy*. 2007; 27:1558-1570.

Marmur JD, Bullock-Palmer RP, Lakhani MJ, Cavusoglu E. Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention. *J Invasive Cardiol* 2006; 18 Suppl E: 1E-13E.

Bullock-Palmer RP, Lakhani MJ, Marmur JD. Lessons learned from the use of low-molecular-weight heparin in the cardiac catheterization laboratory- a series of case reports. *J Invasive Cardiol* 2006; 18 Suppl E: 14E-18E.

Kokolis S, Clark LT, Cavusoglu E, Marmur JD. Direct thrombin inhibitor use during percutaneous coronary intervention. *J Cardiovasc Pharmacol*. 2005;45:270-279.

Kokolis S, Cavusoglu E, Clark LT, Marmur JD. Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors. *Prog Cardiovasc Dis*. 2004;46:506-23.

Cavusoglu E, Chhabra S, Marmur JD, Kini A, Sharma SK. The prevention of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. *Minerva Cardioangiol*. 2004;52:419-32.

Cavusoglu E, Kini AS, Marmur JD, Sharma SK. Current status of rotational atherectomy. *Catheter Cardiovasc Interv*. 2004;62:485-98.

Chopra V, Marmur JD, Cavusoglu E. The role of clopidogrel in the management of patients with ischemic heart disease. *Cardiovasc Drugs Ther*. 2003;17:467-77.

Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD. Membrane-associated CD40L and sCD40L in atherothrombotic disease. *Thromb Haemost* 2003;90:377-84.

Cavusoglu E, Cheng J, Bhatt R, Kunamneni PB, Marmur JD, Eng C. Clopidogrel in the management of ischemic heart disease. *Heart Dis* 2003;5:144-52.

Marmur JD. Direct versus indirect thrombin inhibition in percutaneous coronary intervention. *J Invasive Cardiol* 2002;14 Suppl B:8B-18B.

Doshi SN and Marmur JD. Evolving role of tissue factor and its inhibitor. *Crit Care Med* 2002;30 (5 Suppl):S241-S250.

Marmur JD and Cavusoglu E. The use of the glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary intervention. *J Intervent Cardiol* 2002;15:71-84.

Taubman MB, Fallon JT, Schechter AD, Giesen P, Mendlowitz M, Fyfe BS, Marmur JD, Nemerson Y. Tissue factor in the pathogenesis of atherosclerosis. *Thromb Haemost* 1997;78:200-204.

Marmur JD, Taubman MB, Fuster V. The pathophysiology of restenosis: the role of platelets and thrombin. *J Vasc Med Biol* 1993;4:55-63.

Marmur JD, Poon M, Rossikhina M, Taubman MB. Induction of PDGF-responsive genes in vascular smooth muscle. Implications for the early response to vessel injury. *Circulation* 1992;86(Suppl III):III-53-III-60.

BOOK CHAPTERS

Marmur JD, Mitre C. Management of Acute Coronary Syndromes in Diabetic Patients, in Clark LT (ed.): Cardiovascular Disease and Diabetes. New York, McGraw-Hill, 2006; 67-88.

Lakhani, M, Kokolis S, Cavusoglu, Soff G, Marmur JD. Hemostatic Abnormalities in Diabetes: Hematology for the Cardiologist, in Clark LT (ed.): Cardiovascular Disease and Diabetes. New York, McGraw-Hill, 2006; 402-455.

Fier CM and Marmur JD. Gene Therapy to Stabilize Atherosclerotic Plaque. In Brown DL, ed. Cardiovascular Plaque Rupture. Marcel Dekker, Inc., New York, NY, 2002; 483-504.

Marmur JD. Gene Therapy and the Vessel Wall. In Marks A and Taubman MB, ed. Molecular Biology of Cardiovascular Disease. Marcel Dekker, Inc., New York, NY, 1997; 379-400.

Marmur JD and Venditto J. Biochemical Markers and Complex Lesion Morphology. In Ambrose JA, ed. Complex Coronary Lesions in Acute Coronary Syndromes. Futura Publishing Co., Armonk, NY, 1995; 117-139.

Taubman MB, Poon M, Marmur JD, Wax SD. Gene induction in vessel wall injury: implications for restenosis after angioplasty. In: Woodford FP, Davignon J, Sniderman A, ed. Atherosclerosis X. Amsterdam: Elsevier Science B. V., 1995; 1024-1027.

INVITED LECTURES

October 2008: (i) Moderator of Interventional Pharmacology Board Review. (ii) Anti-thrombins for ACS: UFH/LMWH ± upstream IIb/IIIa is still the best option. (iii) Dual antiplatelet and DES guidelines. Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Sessions, Washington, DC.

October 2007: (i) New Insights Into Glycoprotein IIb/IIIa Inhibitor Use: Bolus Only GP IIb/IIIa Inhibition During PCI. (ii) Controversies in Adjunct Pharmacology: Low Molecular Weight Heparin in ACS and PCI. Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Sessions, Washington, DC.

June 2005: The Evolving Role of Anticoagulation in Coronary Intervention. 3rd Annual New Jersey Cardiovascular Symposium: An Update in the Management of Acute Coronary Syndromes and Heart Failure. Newark, NJ.

March 2005: Unfractionated Heparin Is Obsolete in the Cath Lab-Opening Arguments/Rebuttal, Protagonist. Debate at the ACC Annual Scientific Sessions, Orlando, FL.

September 2004: Monitoring of Low Molecular Weight Heparins - from Theory to Practice. Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Sessions, Washington, DC.

April 2004: Enoxaparin in Acute Coronary Syndromes and Percutaneous Coronary Intervention. Interventional Cardiology Review Course, San Jose, CA.

September 2003: The Emerging Role of Natriuretic Peptides in Percutaneous Coronary Intervention. Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Sessions, Washington, DC.

July 2003: Anticoagulant effects of LMWHs in surgical and interventional indications. Presented to the WHO Working Group on Unfractionated Heparin and Low Molecular Weight Heparin / Working Party on Monitoring of Low Molecular Weight Heparin. Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis, 49th Annual Meeting, Birmingham, UK

June 2003: Intravenous Low Molecular Weight Heparin During PCI. Tenth International Symposium on Thromboembolism, London, England.

March 2003: Role and Controversies of Antithrombin Therapy in the Cardiac Catheterization Laboratory. 4th Annual Antithrombotic Therapy Symposium, Detroit, MI.

January 2003: Adjunct Pharmacology for PCI. Cardiovascular Revascularization Therapy 2003, Washington, DC.

Oct. 2002: Anti-inflammatory Effects of Anti-platelet Agents. Sixth Annual Scientific Meeting of the Institute of Cardiovascular Science and Medicine, Hong Kong.

September 2002: Low Molecular Weight Heparins and Direct Thrombin Inhibitors. Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Sessions, Washington, DC.

June 2002: Monitoring Antithrombotic Therapy During Arterial Intervention. Ninth International Symposium on Thromboembolism, Seville, Spain.

September 2001: GPIIb/IIIa Inhibitors- New Trial Insights and Controversies. Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Sessions, Washington, DC.

July 2001: Direct Thrombin Inhibition in Percutaneous Coronary Intervention. Second International Congress on Heart Disease, Washington, DC.

June 2001: Monitoring Low Molecular Weight Heparins During Coronary Intervention. Eighth International Symposium on Thromboembolism, Florence, Italy.

May 2001: Challenges in the Modern Management of Complex Coronary and Peripheral Vascular Disease. Scripps Memorial Hospital, La Jolla, CA.

March 2001: State of the Art Antithrombotic Therapy 2001. LMWH in Interventional Cardiology. Wayne State University, Dearborn, MI.

March 2001: Adenoviral-mediated Angiogenic Gene Therapy. Annual Scientific Sessions of the American College of Cardiology, Orlando, FL.

Nov. 2000: Low Molecular Weight Heparins in Coronary Intervention. Annual Scientific Sessions of the American Heart Association, New Orleans, LA.

Oct. 2000: Oral Antiplatelet Agents. Interventional Cardiology Review Course, Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium , Washington, DC.

August 2000: Congress of the European Society of Cardiology. Differentiation of Glycoprotein IIb/IIIa Inhibitors. Amsterdam, The Netherlands.

May 2000: Paris Course on Revascularization. Switching Patients from Small Molecules to Abciximab. Paris, France.

March 2000: Alternative Revascularization Strategies: PMR/DMR and Angiogenesis. Evening session panelist at the American College of Cardiology 49th Annual Scientific Sessions, Anaheim, CA.

Oct. 1999: Tirofiban in the Management of Acute Coronary Syndromes. Symposium on Platelet GP IIb/IIIa Inhibitors. Lisbon, Portugal.

Oct. 1999: Congress of the Korean Society of Circulation. Platelets as the target in thrombus formation. Seoul, Korea.

Sept. 1999: Aspirin and Thienopyridines. Interventional Cardiology Review Course, Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium , Washington, DC.

Sept. 1999: Keynote Address: New Pharmacologic Adjuncts in Coronary Intervention. Cardiac Intervention in Chicagoland, Chicago, Illinois.

Sept. 1999: ACS Debate Club. Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Sessions, Washington, DC.

Sept. 1999: Platelet Receptor Inhibitors. Cardiology Grand Rounds, University of Virginia, Charlottesville, VA.

August 1999: Acute Myocardial Infarction: Invasive versus Medical Therapy. Invitational Cardiology Symposium, Akron General Medical Center, Akron, OH.

June 1999: Gene Therapy for Therapeutic Angiogenesis. A Live Symposium of Complex Coronary Cases. New York, NY.

April 1999: Platelet Glycoprotein IIb/IIIa Receptor Blockers in Coronary Interventions: What Did We Learn from EPIC, EPILOG, EPISTENT, RESTORE, and IMPACT II? Boston, MA

March 1999: GPIIb/IIIa Inhibition in Acute Coronary Syndromes Management. CME Symposium at the 1999 Annual Meeting of the American College of Cardiology. New Orleans, LA.

Jan. 1999: Indications for GP IIb/IIIa Inhibitors in Acute Coronary Syndromes and Percutaneous Coronary Interventions. St. Louis University Hospital, St. Louis, MO.

Nov. 1998: New Paradigm in the Treatment of Acute Coronary Syndromes. The Role of Troponin and IIb/IIIa Inhibitor Therapy. Stony Brook University Hospital, NY.

Sept. 1998: Interventional Cardiology Update 98. CK versus Troponin in the Diagnosis of Acute Coronary Syndromes and Periprocedural CK Elevation. Orlando, FL.

Sept. 1998: The Bernard and Helen Perlman Lecture: Platelet GP IIb/IIIa Receptor Blockers. The New York Cardiological Society, Inc. 70th Anniversary Program on Emerging Issues in the Practice of Cardiology. New York, NY.

July 1998: Acute Coronary Syndromes: Incorporating New Therapies to an Established Algorithm of Care. Hartford, CT

June 1998: Gene Therapy for the Management of In-stent Restenosis. A Live Symposium of Complex Coronary Cases. New York, NY.

June 1998: Molecular Biology of Restenosis. Current Medical and Interventional Therapy in Acute Coronary Syndromes. New York, NY.

April 1990: The Acute Biological Response to Excimer Versus Thermal Laser Angioplasty in Experimental Atherosclerosis. Symposium on Laser Angioplasty. University Hospital Utrecht, Maastricht, The Netherlands.

MEDIA RESOURCE EDUCATIONAL MATERIALS

CD-ROM: Low Molecular Weight Heparin in the Cardiac Catheterization Laboratory. September 2002. (produced by alphaMED, New York, NY, and the Annenberg Center for Health Sciences at Eisenhower, 39000 Bob Hope Drive, Rancho Mirage, CA 92270).

CD-ROM: The Evolving Role of Tissue Factor and its Inhibitor, TFPI. The Margaux Conference on Critical Illness, Sedona, AZ 2001 (produced by Remedica Communications, UK; www.remedica.com).

CD-ROM: Antithrombotic drugs in Interventional Cardiology. 8th International Symposium on Thromboembolism. Palazao dei Congressi, Florence, Italy 2001 (produced by Remedica Communications, UK; www.remedica.com).

CD-ROM: ACC Spotlight Series: ACCIS 2001. Alternative Revascularization Strategies. Orlando, FL 2001 (produced by PhysicianEd, Boston, MA).

CD-ROM: Oral antiplatelet therapy. 3rd Annual Interventional Cardiology Self-Assessment Course. Washington, DC 2000 (produced by The Cardiovascular Research Foundation).

CD-ROM: GP IIb/IIIa Inhibition in Acute Coronary Syndromes- Science and Practice. New Orleans, LA 1999 (produced by Conceptis Technologies, Montreal, Canada).

PATENTS

Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) is an Independent Predictor of All-Cause Mortality, Cardiac Mortality, and Myocardial Infarction. Submitted December 2, 2004 by The Research Foundation of the State University of New York (SUNY). For more information, visit: www.RFSUNY.org.